1. From the Department of Ophthalmology, Emory University, Atlanta, Georgia;
2. Omar Consulting Group, Princeton Junction, New Jersey;
3. Allergan Inc., Irvine, California;
4. the Doheny Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, California;
5. Pfizer, La Jolla, California;
6. the Department of Pharmaceutical Sciences, University of Strathclyde, Glasgow, Scotland;
7. MacuSight, Union City, California;
8. the Gavin Herbert Eye Institute, University of California-Irvine Medical School, Irvine, California;
9. the Department of Ophthalmology, Duke University School of Medicine, Durham, North Carolina;
10. the Department of Pharmaceutical Sciences, University of Colorado-Denver, Aurora, Colorado;
11. Taligen Therapeutics, Boston, Massachusetts;
12. the Department of Ophthalmology and Visual Sciences, Cell Biology and Functional Genomics Laboratory, The University of Iowa, Iowa City, Iowa;
13. the Department of Clinical Sciences, North Carolina State University, College of Veterinary Medicine, Raleigh, North Carolina;
14. Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland; and
15. the National Eye Institute, National Institutes of Health, Bethesda, Maryland.